MASSDEVICE ON CALL — A nationwide urologists lobbying group largely discredited guidance from a U.S. Preventative Services Task Force recommending that physicians set aside a commonly used prostate cancer screening tool.
Known as the prostate-specific antigen test, or PSA, the tool may pose more risks than benefits, according to the panel.